Pull the brake off noradrenaline
IUPAC: methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate · C21H26N2O3 · MW 354.45 g/mol · CAS 146-48-5
Yohimbine. Corynanthe-type indole alkaloid from the bark of the West African tree Pausinystalia johimbe (and from Rauwolfia species). It is the pharmacological mirror image of an α2-agonist like clonidine: where clonidine tells the noradrenergic system to shut up, yohimbine rips the presynaptic brake off and lets norepinephrine run. Classic autonomic-pharmacology probe, folk aphrodisiac, and gym fat-burner. Also traded as: yohimbe bark extract, Yocon, Aphrodyne, "yohimbine HCl."
Yohimbine is a competitive, reversible antagonist at α2-adrenergic receptors (α2A, α2B, α2C). The α2-AR is a Gi/o-coupled GPCR that, as a presynaptic autoreceptor on noradrenergic terminals, provides negative feedback: released norepinephrine (NE) binds α2A autoreceptors, inhibits adenylyl cyclase, closes Ca2+ channels, and shuts down further NE release. By occupying that autoreceptor without activating it, yohimbine severs the feedback loop — the noradrenergic system loses its brake and NE outflow rises sharply across the CNS and periphery. This is the pharmacological inverse of clonidine or dexmedetomidine (α2 agonists that suppress NE release).
Yohimbine occupies the orthosteric pocket of the presynaptic α2A autoreceptor (Ki ~0.4–7.5 nM) without triggering Gi coupling. Loss of feedback inhibition increases the firing of locus coeruleus neurons and the amount of NE released per action potential.
High affinity at α2B (Ki ~2 nM) and α2C (Ki ~2.3 nM). α2C is enriched in basal ganglia and modulates catecholamine release under stress; α2B mediates peripheral vasoconstriction — relevant to yohimbine's blood-pressure effects.
Disinhibited LC firing floods cortex, amygdala, and hippocampus with NE, driving arousal, vigilance, and — at higher exposure — frank anxiety and panic. This is why yohimbine is used experimentally as a noradrenergic stress/panic probe.
Blocking α2 receptors on sympathetic terminals and adrenal medulla raises circulating catecholamines → tachycardia, hypertension, sweating, tremor, mydriasis. In adipose tissue, α2 blockade removes an anti-lipolytic restraint (the basis of the "fat-burner" claim).
Yohimbine is not clean: it binds 5-HT1A (reported partial-agonist activity, low-µM), plus 5-HT1B/1D and 5-HT2 receptors (5-HT2A Ki ~1.6 µM). This serotonergic component modulates the subjective profile and is one reason interactions with serotonergic drugs are unpredictable.
Affinity for α1-adrenergic receptors is 100–1000× weaker (Ki ~50–1000 nM). This α2-over-α1 selectivity is what makes yohimbine a net sympathoexciter rather than a pressor-blocker, and distinguishes it from non-selective agents like phentolamine.
Yohimbine is rapidly but unpredictably absorbed after oral dosing. Reported oral bioavailability ranges from roughly 7% to 86% between individuals (Owen et al. 1987) — one of the most erratic PK profiles among common bioactives, driven by first-pass metabolism and pharmacogenetic variation. Plasma half-life of the parent is short (~0.6 h), so acute effects are brief, but an active metabolite extends and complicates the picture.
Metabolism cascade: Yohimbine is oxidized primarily by CYP2D6 (with a minor CYP3A4 contribution) to hydroxylated metabolites. 11-hydroxyyohimbine is pharmacologically active — it retains substantial α2-antagonist potency and has a longer half-life than the parent, meaning it, not yohimbine itself, may sustain much of the systemic α2 blockade after the parent has cleared (Le Corre et al. 1999).
CYP2D6 pharmacogenetics matter here. Poor metabolizers (~7–10% of Europeans) clear yohimbine slowly and reach far higher parent-drug exposure at a given dose — with correspondingly greater blood-pressure and anxiety responses. Because CYP2D6 also metabolizes many antidepressants and antipsychotics, co-medication that inhibits CYP2D6 can convert a "normal" metabolizer into a functional poor metabolizer, amplifying yohimbine's effect unpredictably.
Yohimbine's subjective and physiological profile is dominated by the noradrenergic surge it produces. Unlike a dopaminergic stimulant (cocaine, amphetamine), yohimbine's "stimulation" is autonomic and affective rather than euphoric: heightened arousal, alertness, restlessness, and — at higher doses in susceptible people — anxiety, dread, and panic. This is not a side effect; it is the pharmacology.
Loss of α2A autoreceptor feedback increases LC tonic firing and NE release across its vast cortical projection field. The result is a state of hypervigilance and stimulant-like arousal, mediated by post-synaptic α1 and β adrenoceptors — attention narrows, sensory gain rises, sleep is suppressed.
NE flooding the basolateral amygdala and bed nucleus of the stria terminalis (BNST) drives threat processing and fear expression. Yohimbine reliably provokes anxiety and, in panic-disorder and PTSD patients, frank panic attacks and flashbacks — which is exactly why it is used as an experimental challenge agent to probe noradrenergic dysregulation (Charney et al. 1984; Southwick et al. 1993).
Direct binding at 5-HT1A (partial agonist) and 5-HT2 receptors overlays the noradrenergic core with a serotonergic component that modulates mood and anxiety and blurs clean interpretation. It also means yohimbine is not a "pure" α2 tool in vivo, and that serotonergic co-drugs can interact in hard-to-predict ways.
Central and peripheral α2 blockade increases sympathetic and parasympathetic drive to the genitalia and can facilitate penile blood flow and erection — the mechanistic basis of yohimbine's centuries-old reputation as an aphrodisiac and its 20th-century use for erectile dysfunction, now superseded by PDE5 inhibitors.
The through-line: yohimbine converts tonic noradrenergic restraint into noradrenergic excess. Whether that registers as "energizing," "anxious," or "aphrodisiac" depends heavily on dose, individual CYP2D6 status, baseline anxiety, and set/setting — which is why its effects are famously inconsistent between users.
Few molecules straddle so many worlds. Yohimbine bark has been used in West Africa as an aphrodisiac and stimulant for centuries. In 20th-century medicine, prescription yohimbine (Yocon, Aphrodyne) was a pre-Viagra treatment for erectile dysfunction — modestly effective versus placebo in meta-analysis, but eclipsed by PDE5 inhibitors after 1998. It has also been studied for orthostatic hypotension (raising sympathetic tone) and, experimentally, as an adjunct to extinction-based therapy for anxiety disorders (leveraging noradrenergic enhancement of learning).
The fat-loss claim: α2 receptors on adipocytes are anti-lipolytic; blocking them removes a brake on fat mobilization, and yohimbine can increase lipolysis and fat oxidation, especially in the fasted state and in α2-rich "stubborn" fat depots. Effect sizes in humans are small and the data are thin — this is a real mechanism producing a marginal, not miraculous, result.
Unpredictable dosing is the core hazard. "Yohimbe bark extract" supplements are notoriously mislabeled: an FDA-funded analysis (Cohen et al. 2016, Drug Test Anal) found the actual yohimbine content of commercial products ranged from undetectable to more than double the label, with most providing no quantitative dosing information at all. A consumer cannot know how much α2-antagonist they are swallowing — combined with the erratic oral bioavailability and CYP2D6 variability, the same product can be inert in one person and cause a hypertensive, panic-inducing reaction in another.
As a research reagent, yohimbine is a workhorse: an α2-antagonist tool compound, a validated anxiety/panic-provocation challenge in humans, and a robust trigger for stress-induced reinstatement of drug- and food-seeking in animal models of relapse.
Yohimbine is a nearly rigid pentacyclic scaffold — five fused rings (indole + the
yohimban quinolizidine cage) leaving essentially one rotatable bond (the C16 carbomethoxy ester;
RTB = 1 per ChEMBL). It arrives at the α2 orthosteric pocket almost fully pre-organized, so the
ΔS_conf penalty on binding — the ligand's own loss of conformational freedom — is very small.
Nearly all of the binding free energy is available as enthalpy and desolvation, consistent with the
sub-nanomolar α2A Ki measured for such a compact molecule.
The receptor side tells the interesting story. An antagonist like yohimbine binds the α2
orthosteric site (visualized here in the α2C structure PDB 6KUW) and
traps the receptor in an inactive-state conformation, forbidding the collapse of the
transmembrane helix bundle (notably the TM6 inward movement) that agonists require for Gi
coupling. In Shannon-entropy terms, the apo receptor samples a broad ensemble of conformers
(high H_pocket); yohimbine binding collapses that ensemble onto the inactive basin —
entropy collapse without activation. This is the thermodynamic signature that distinguishes a
high-affinity antagonist from an agonist: the pocket is silenced, not switched on.
Predicted ΔG_bind for the α2A:yohimbine complex (tENCoM-informed, FlexAID∆S
ensemble): approximately −12 to −13 kcal/mol, in the range expected from the observed
Ki ≈ 0.4 nM (theoretical ΔG = −RT·ln(Ka) ≈ −12.7 kcal/mol at 298 K). The rigid cage
minimizes the entropic cost of that tight fit — a textbook case of pre-organization buying affinity.
Yohimbine is legal and marketed as a supplement, which disguises a genuinely cardioactive drug with a hazardous interaction profile. Risks are dose-dependent, individually variable, and driven almost entirely by unchecked noradrenergic tone.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
α2A
Adrenergic α2A (ADRA2A)
|
Ki = 0.42 nM
also 7.5 nM (2nd assay)
|
Antagonist | |
|
α2B
Adrenergic α2B (ADRA2B)
|
Ki = 2.0 nM
|
Antagonist | |
|
α2C
Adrenergic α2C (ADRA2C)
|
Ki = 2.3 nM
|
Antagonist | |
|
α1
Adrenergic α1 (A/B/D)
|
Ki ≈ 50–1000 nM
100–1000× weaker
|
Weak antag. | |
|
5-HT2A
Serotonin 2A (HTR2A)
|
Ki ≈ 1,620 nM
+ 5-HT1A (low-µM)
|
Serotonergic |